Literature DB >> 12973034

Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery.

Richard C Koya1, Nori Kasahara, Patricia M B Favaro, Roy Lau, Huy Q Ta, Jeffrey S Weber, Renata Stripecke.   

Abstract

Dendritic cells (DCs) are being evaluated in immunization protocols to enhance immunity against infectious diseases and cancer. Interaction of T-helper cells expressing CD40 ligand (CD40L) with its cognate CD40 receptor on DCs leads to a mature DC phenotype, characterized by increased capacity of antigen presentation to cytotoxic T cells. The authors examined the ability of third-generation self-inactivating lentiviral vectors expressing CD40L to induce autonomous maturation of ex vivo expanded human monocyte-derived dendritic cells. Transduction with lentiviral vectors achieved a highly efficient gene transfer of CD40L to DCs, which correlated with phenotypic maturation as shown by the expression of immunologic relevant markers (CD83, CD80, MHCI) and secretion of IL-12, whereas DC phenotype was not affected by a control vector expressing only the green fluorescent protein marker. Addition of recombinant IFN-gamma to DCs at the time of CD40L transduction further enhanced IL-12 production, and when co-cultured with allogeneic and autologous CD8+ and CD4+ T cells, a potent activation was observed. Autologous responses against an HLA-A2-restricted influenza peptide (Flu-M1) and a tumor-associated antigenic peptide (gp100 210M) were significantly enhanced when CD40L transduced DCs were used as antigen-presenting cells for in vitro stimulation of CD8+ cytotoxic T lymphocytes. These results demonstrate that endogenous expression of CD40L by lentivirally transduced DCs induced their autonomous maturation to a phenotype comparable to that induced by optimal concentrations of soluble CD40L, providing a novel tool for genetic manipulation of DCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973034     DOI: 10.1097/00002371-200309000-00008

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  18 in total

Review 1.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.

Authors:  Rongxin Zhang; Sheng Zhang; Min Li; Changyi Chen; Qizhi Yao
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

3.  EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.

Authors:  Sachin Gupta; James M Termini; Liguo Niu; Saravana K Kanagavelu; Helena Schmidtmayerova; Victoria Snarsky; Richard S Kornbluth; Geoffrey W Stone
Journal:  J Leukoc Biol       Date:  2011-05-17       Impact factor: 4.962

Review 4.  Recent Advances in Good Manufacturing Practice-Grade Generation of Dendritic Cells.

Authors:  Sarah Cunningham; Holger Hackstein
Journal:  Transfus Med Hemother       Date:  2020-10-28       Impact factor: 3.747

5.  Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection.

Authors:  Thomas D Norton; Takuya Tada; Rebecca Leibowitz; Verena van der Heide; Dirk Homann; Nathaniel R Landau
Journal:  Mol Ther       Date:  2020-05-20       Impact factor: 11.454

Review 6.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

Review 7.  Lentiviral vectors in gene therapy: their current status and future potential.

Authors:  David Escors; Karine Breckpot
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-02-09       Impact factor: 4.291

8.  The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy.

Authors:  Paul C Tumeh; Richard C Koya; Thinle Chodon; Nicholas A Graham; Thomas G Graeber; Begoña Comin-Anduix; Antoni Ribas
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

Review 9.  Engineering dendritic cells to enhance cancer immunotherapy.

Authors:  Jeanette E Boudreau; Aude Bonehill; Kris Thielemans; Yonghong Wan
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

10.  Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris.

Authors:  Francesca Chamian; Michelle A Lowes; Shao-Lee Lin; Edmund Lee; Toyoko Kikuchi; Patricia Gilleaudeau; Mary Sullivan-Whalen; Irma Cardinale; Artemis Khatcherian; Inna Novitskaya; Knut M Wittkowski; James G Krueger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.